Dissecting cellular responses to irradiation via targeted disruptions of the ATM-CHK1-PP2A circuit

References

• Martín M, Terradas M, Tusell L, Genescà A. ATM and DNA-PKcs make a complementary couple in DNA double-strand break repair. Mutat Res 2012; 751:29 - 35; http://dx.doi.org/10.1016/j.mrrev.2011.12.006; PMID: 22230547
   PubMed Web of Science ®Google Scholar
• Smith J, Tho LM, Xu N, Gillespie DA. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv Cancer Res 2010; 108:73 - 112; http://dx.doi.org/10.1016/B978-0-12-380888-2.00003-0; PMID: 21034966
   PubMed Web of Science ®Google Scholar
• Kass EM, Jasin M. Collaboration and competition between DNA double-strand break repair pathways. FEBS Lett 2010; 584:3703 - 8; http://dx.doi.org/10.1016/j.febslet.2010.07.057; PMID: 20691183
   PubMed Web of Science ®Google Scholar
• Shrivastav M, De Haro LP, Nickoloff JA. Regulation of DNA double-strand break repair pathway choice. Cell Res 2008; 18:134 - 47; http://dx.doi.org/10.1038/cr.2007.111; PMID: 18157161
   PubMed Web of Science ®Google Scholar
• Sørensen CS, Hansen LT, Dziegielewski J, Syljuåsen RG, Lundin C, Bartek J, et al. The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. Nat Cell Biol 2005; 7:195 - 201; http://dx.doi.org/10.1038/ncb1212; PMID: 15665856
   PubMed Web of Science ®Google Scholar
• Enders GH. Expanded roles for Chk1 in genome maintenance. J Biol Chem 2008; 283:17749 - 52; http://dx.doi.org/10.1074/jbc.R800021200; PMID: 18424430
   PubMed Web of Science ®Google Scholar
• Ha K, Lee GE, Palii SS, Brown KD, Takeda Y, Liu K, et al. Rapid and transient recruitment of DNMT1 to DNA double-strand breaks is mediated by its interaction with multiple components of the DNA damage response machinery. Hum Mol Genet 2011; 20:126 - 40; http://dx.doi.org/10.1093/hmg/ddq451; PMID: 20940144
   PubMed Web of Science ®Google Scholar
• Palii SS, Van Emburgh BO, Sankpal UT, Brown KD, Robertson KD. DNA methylation inhibitor 5-Aza-2′-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B. Mol Cell Biol 2008; 28:752 - 71; http://dx.doi.org/10.1128/MCB.01799-07; PMID: 17991895
   PubMed Web of Science ®Google Scholar
• Shimada M, Niida H, Zineldeen DH, Tagami H, Tanaka M, Saito H, et al. Chk1 is a histone H3 threonine 11 kinase that regulates DNA damage-induced transcriptional repression. Cell 2008; 132:221 - 32; http://dx.doi.org/10.1016/j.cell.2007.12.013; PMID: 18243098
   PubMed Web of Science ®Google Scholar
• Bucher N, Britten CD. G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer. Br J Cancer 2008; 98:523 - 8; http://dx.doi.org/10.1038/sj.bjc.6604208; PMID: 18231106
   PubMed Web of Science ®Google Scholar
• Dai Y, Grant S. Targeting Chk1 in the replicative stress response. Cell Cycle 2010; 9:1025; http://dx.doi.org/10.4161/cc.9.6.11155; PMID: 20237419
   PubMed Web of Science ®Google Scholar
• Ma CX, Janetka JW, Piwnica-Worms H. Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics. Trends Mol Med 2011; 17:88 - 96; http://dx.doi.org/10.1016/j.molmed.2010.10.009; PMID: 21087899
   PubMed Web of Science ®Google Scholar
• Arlander SJ, Greene BT, Innes CL, Paules RS. DNA protein kinase-dependent G2 checkpoint revealed following knockdown of ataxia-telangiectasia mutated in human mammary epithelial cells. Cancer Res 2008; 68:89 - 97; http://dx.doi.org/10.1158/0008-5472.CAN-07-0675; PMID: 18172300
   PubMed Web of Science ®Google Scholar
• Leung-Pineda V, Ryan CE, Piwnica-Worms H. Phosphorylation of Chk1 by ATR is antagonized by a Chk1-regulated protein phosphatase 2A circuit. Mol Cell Biol 2006; 26:7529 - 38; http://dx.doi.org/10.1128/MCB.00447-06; PMID: 17015476
   PubMed Web of Science ®Google Scholar
• Freeman AK, Monteiro AN. Phosphatases in the cellular response to DNA damage. Cell Commun Signal 2010; 8:27; http://dx.doi.org/10.1186/1478-811X-8-27; PMID: 20860841
   PubMed Web of Science ®Google Scholar
• Shouse GP, Cai X, Liu X. Serine 15 phosphorylation of p53 directs its interaction with B56γ and the tumor suppressor activity of B56γ-specific protein phosphatase 2A. Mol Cell Biol 2008; 28:448 - 56; http://dx.doi.org/10.1128/MCB.00983-07; PMID: 17967874
   PubMed Web of Science ®Google Scholar
• Yan Y, Cao PT, Greer PM, Nagengast ES, Kolb RH, Mumby MC, et al. Protein phosphatase 2A has an essential role in the activation of γ-irradiation-induced G2/M checkpoint response. Oncogene 2010; 29:4317 - 29; http://dx.doi.org/10.1038/onc.2010.187; PMID: 20498628
   PubMed Web of Science ®Google Scholar
• Chen J, Martin BL, Brautigan DL. Regulation of protein serine-threonine phosphatase type-2A by tyrosine phosphorylation. Science 1992; 257:1261 - 4; http://dx.doi.org/10.1126/science.1325671; PMID: 1325671
   PubMed Web of Science ®Google Scholar
• Chen J, Parsons S, Brautigan DL. Tyrosine phosphorylation of protein phosphatase 2A in response to growth stimulation and v-src transformation of fibroblasts. J Biol Chem 1994; 269:7957 - 62; PMID: 7510677
   PubMed Web of Science ®Google Scholar
• Ray S, Anderson ME, Tegtmeyer P. Differential interaction of temperature-sensitive simian virus 40 T antigens with tumor suppressors pRb and p53. J Virol 1996; 70:7224 - 7; PMID: 8794371
   PubMed Web of Science ®Google Scholar
• Meyer KM, Hess SM, Tlsty TD, Leadon SA. Human mammary epithelial cells exhibit a differential p53-mediated response following exposure to ionizing radiation or UV light. Oncogene 1999; 18:5795 - 805; http://dx.doi.org/10.1038/sj.onc.1202977; PMID: 10523860
   PubMed Web of Science ®Google Scholar
• Troester MA, Hoadley KA, Sørlie T, Herbert BS, Børresen-Dale AL, Lønning PE, et al. Cell-type-specific responses to chemotherapeutics in breast cancer. Cancer Res 2004; 64:4218 - 26; http://dx.doi.org/10.1158/0008-5472.CAN-04-0107; PMID: 15205334
   PubMed Web of Science ®Google Scholar
• Zhang J, Pickering CR, Holst CR, Gauthier ML, Tlsty TD. p16INK4a modulates p53 in primary human mammary epithelial cells. Cancer Res 2006; 66:10325 - 31; http://dx.doi.org/10.1158/0008-5472.CAN-06-1594; PMID: 17079452
   PubMed Web of Science ®Google Scholar
• Jiang H, Reinhardt HC, Bartkova J, Tommiska J, Blomqvist C, Nevanlinna H, et al. The combined status of ATM and p53 link tumor development with therapeutic response. Genes Dev 2009; 23:1895 - 909; http://dx.doi.org/10.1101/gad.1815309; PMID: 19608766
   PubMed Web of Science ®Google Scholar
• Gagou ME, Zuazua-Villar P, Meuth M. Enhanced H2AX phosphorylation, DNA replication fork arrest, and cell death in the absence of Chk1. Mol Biol Cell 2010; 21:739 - 52; http://dx.doi.org/10.1091/mbc.E09-07-0618; PMID: 20053681
   PubMed Web of Science ®Google Scholar
• Kim MA, Kim HJ, Brown AL, Lee MY, Bae YS, Park JI, et al. Identification of novel substrates for human checkpoint kinase Chk1 and Chk2 through genome-wide screening using a consensus Chk phosphorylation motif. Exp Mol Med 2007; 39:205 - 12; http://dx.doi.org/10.1038/emm.2007.23; PMID: 17464182
   PubMed Web of Science ®Google Scholar
• Lee HJ, Hwang HI, Jang YJ. Mitotic DNA damage response: Polo-like kinase-1 is dephosphorylated through ATM-Chk1 pathway. Cell Cycle 2010; 9:2389 - 98; http://dx.doi.org/10.4161/cc.9.12.11904; PMID: 20581453
   PubMed Web of Science ®Google Scholar
• Bertoni F, Codegoni AM, Furlan D, Tibiletti MG, Capella C, Broggini M. CHK1 frameshift mutations in genetically unstable colorectal and endometrial cancers. Genes Chromosomes Cancer 1999; 26:176 - 80; http://dx.doi.org/10.1002/(SICI)1098-2264(199910)26:2<176::AID-GCC11>3.0.CO;2-3; PMID: 10469457
   PubMed Web of Science ®Google Scholar
• Menoyo A, Alazzouzi H, Espín E, Armengol M, Yamamoto H, Schwartz S Jr.. Somatic mutations in the DNA damage-response genes ATR and CHK1 in sporadic stomach tumors with microsatellite instability. Cancer Res 2001; 61:7727 - 30; PMID: 11691784
   PubMed Web of Science ®Google Scholar
• Liu Q, Guntuku S, Cui XS, Matsuoka S, Cortez D, Tamai K, et al. Chk1 is an essential kinase that is regulated by Atr and required for the G2/M DNA damage checkpoint. Genes Dev 2000; 14:1448 - 59; PMID: 10859164
   PubMed Web of Science ®Google Scholar
• Lam MH, Liu Q, Elledge SJ, Rosen JM. Chk1 is haploinsufficient for multiple functions critical to tumor suppression. Cancer Cell 2004; 6:45 - 59; http://dx.doi.org/10.1016/j.ccr.2004.06.015; PMID: 15261141
   PubMed Web of Science ®Google Scholar
• Fishler T, Li YY, Wang RH, Kim HS, Sengupta K, Vassilopoulos A, et al. Genetic instability and mammary tumor formation in mice carrying mammary-specific disruption of Chk1 and p53. Oncogene 2010; 29:4007 - 17; http://dx.doi.org/10.1038/onc.2010.163; PMID: 20473325
   PubMed Web of Science ®Google Scholar
• Verlinden L, Vanden Bempt I, Eelen G, Drijkoningen M, Verlinden I, Marchal K, et al. The E2F-regulated gene Chk1 is highly expressed in triple-negative estrogen receptor-/progesterone receptor-/HER-2- breast carcinomas. Cancer Res 2007; 67:6574 - 81; http://dx.doi.org/10.1158/0008-5472.CAN-06-3545; PMID: 17638866
   PubMed Web of Science ®Google Scholar
• Tort F, Hernández S, Beà S, Camacho E, Fernández V, Esteller M, et al. Checkpoint kinase 1 (CHK1) protein and mRNA expression is downregulated in aggressive variants of human lymphoid neoplasms. Leukemia 2005; 19:112 - 7; PMID: 15526025
   PubMed Web of Science ®Google Scholar
• Chen P, Gatei M, O’Connell MJ, Khanna KK, Bugg SJ, Hogg A, et al. Chk1 complements the G2/M checkpoint defect and radiosensitivity of ataxia-telangiectasia cells. Oncogene 1999; 18:249 - 56; http://dx.doi.org/10.1038/sj.onc.1202257; PMID: 9926940
   PubMed Web of Science ®Google Scholar
• Carrassa L, Damia G. Unleashing Chk1 in cancer therapy. Cell Cycle 2011; 10:2121 - 8; http://dx.doi.org/10.4161/cc.10.13.16398; PMID: 21610326
   PubMed Web of Science ®Google Scholar
• Ashwell S. Checkpoint kinase and Wee1 inhibitors as anticancer therapeutics. Elsevier Ltd., 2012:211-34.
   Google Scholar
• Davies KD, Humphries MJ, Sullivan FX, von Carlowitz I, Le Huerou Y, Mohr PJ, et al. Single-agent inhibition of Chk1 is antiproliferative in human cancer cell lines in vitro and inhibits tumor xenograft growth in vivo. Oncol Res 2011; 19:349 - 63; http://dx.doi.org/10.3727/096504011X13079697132961; PMID: 21936404
   PubMed Web of Science ®Google Scholar
• Dent P, Tang Y, Yacoub A, Dai Y, Fisher PB, Grant S. CHK1 inhibitors in combination chemotherapy: thinking beyond the cell cycle. Mol Interv 2011; 11:133 - 40; http://dx.doi.org/10.1124/mi.11.2.11; PMID: 21540473
   PubMed Web of Science ®Google Scholar
• Garrett MD, Collins I. Anticancer therapy with checkpoint inhibitors: what, where and when?. Trends Pharmacol Sci 2011; 32:308 - 16; http://dx.doi.org/10.1016/j.tips.2011.02.014; PMID: 21458083
   PubMed Web of Science ®Google Scholar
• Ren Q, Liu R, Dicker A, Wang Y. CHK1 affects cell sensitivity to microtubule-targeted drugs. J Cell Physiol 2005; 203:273 - 6; http://dx.doi.org/10.1002/jcp.20222; PMID: 15389625
   PubMed Web of Science ®Google Scholar
• Greenow KR, Clarke AR, Jones RH. Chk1 deficiency in the mouse small intestine results in p53-independent crypt death and subsequent intestinal compensation. Oncogene 2009; 28:1443 - 53; http://dx.doi.org/10.1038/onc.2008.482; PMID: 19169280
   PubMed Web of Science ®Google Scholar
• Dai Y, Chen S, Shah R, Pei XY, Wang L, Almenara JA, et al. Disruption of Src function potentiates Chk1-inhibitor-induced apoptosis in human multiple myeloma cells in vitro and in vivo. Blood 2011; 117:1947 - 57; http://dx.doi.org/10.1182/blood-2010-06-291146; PMID: 21148814
   PubMed Web of Science ®Google Scholar
• Tao Y, Leteur C, Yang C, Zhang P, Castedo M, Pierré A, et al. Radiosensitization by Chir-124, a selective CHK1 inhibitor: effects of p53 and cell cycle checkpoints. Cell Cycle 2009; 8:1196 - 205; http://dx.doi.org/10.4161/cc.8.8.8203; PMID: 19305158
   PubMed Web of Science ®Google Scholar
• Davies KD, Cable PL, Garrus JE, Sullivan FX, von Carlowitz I, Huerou YL, et al. Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation. Cancer Biol Ther 2011; 12:788 - 96; http://dx.doi.org/10.4161/cbt.12.9.17673; PMID: 21892012
   PubMed Web of Science ®Google Scholar
• Lu HR, Wang X, Wang Y. A stronger DNA damage-induced G2 checkpoint due to over-activated CHK1 in the absence of PARP-1. Cell Cycle 2006; 5:2364 - 70; http://dx.doi.org/10.4161/cc.5.20.3355; PMID: 17102615
   PubMed Web of Science ®Google Scholar
• Jurvansuu J, Fragkos M, Ingemarsdotter C, Beard P. Chk1 instability is coupled to mitotic cell death of p53-deficient cells in response to virus-induced DNA damage signaling. J Mol Biol 2007; 372:397 - 406; http://dx.doi.org/10.1016/j.jmb.2007.06.077; PMID: 17663993
   PubMed Web of Science ®Google Scholar
• Limbo O, Porter-Goff ME, Rhind N, Russell P. Mre11 nuclease activity and Ctp1 regulate Chk1 activation by Rad3ATR and Tel1ATM checkpoint kinases at double-strand breaks. Mol Cell Biol 2011; 31:573 - 83; http://dx.doi.org/10.1128/MCB.00994-10; PMID: 21098122
   PubMed Web of Science ®Google Scholar
• Morgan MA, Parsels LA, Zhao L, Parsels JD, Davis MA, Hassan MC, et al. Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. Cancer Res 2010; 70:4972 - 81; http://dx.doi.org/10.1158/0008-5472.CAN-09-3573; PMID: 20501833
   PubMed Web of Science ®Google Scholar
• Parsels LA, Qian Y, Tanska DM, Gross M, Zhao L, Hassan MC, et al. Assessment of Chk1 phosphorylation as a pharmacodynamic biomarker of Chk1 inhibition. Clin Cancer Res 2011; 17:3706 - 15; http://dx.doi.org/10.1158/1078-0432.CCR-10-3082; PMID: 21482692
   PubMed Web of Science ®Google Scholar